Evidence map›Paper›PMID 33539685›Full record

ArticleCurrent protocols2021

Production of Class II MHC Proteins in Lentiviral Vector-Transduced HEK-293T Cells for Tetramer Staining Reagents.

Richard A Willis, Vasanthi Ramachandiran, John C Shires, Ge Bai, Kelly Jeter, Donielle L Bell, Lixia Han, Tamara Kazarian, Kyla C Ugwu, Oskar Laur and 3 more

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Current protocols, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Transduction of Lentiviral Vectors andInternational journal of molecular sciences · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Richard A WillisEmory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia.
Vasanthi RamachandiranEmory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia.
John C ShiresEmory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia.
Ge BaiEmory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia.
Kelly JeterEmory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia.
Donielle L BellEmory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia.
Lixia HanEmory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia.
Tamara KazarianEmory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia.
Kyla C UgwuEmory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia.
Oskar LaurDepartment of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia.
Susana Contreras-AlcantaraEmory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia.
Dale L LongEmory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia.
John D AltmanEmory Vaccine Center, Emory University School of Medicine, Atlanta, Georgia.
Emory National Primate Research CenterEmory University · USOregon National Primate Research Center · USAtlanta VA Medical Center · US

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE)UL1TR002378 · NCATS · EMORY UNIVERSITY · PI Andres J Garcia, Elizabeth O. Ofili · 2017 to 2026
$92.1M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
Role of antigen-specific T cell responses in the control of TBU19AI111211 · NIAID · EMORY UNIVERSITY · PI RENGARAJAN, JYOTHI · 2014 to 2020
$20.1M
Tetramer Research & Development Contract (Influenza)75N93020D00005 · NIAID · EMORY UNIVERSITY · PI ALTMAN, JOHN · 2020 to 2025
$18.3M
Tetramers for Immune-mediated Diseases Research272201300006C · NIAID · EMORY UNIVERSITY · PI ALTMAN, JOHN · 2013 to 2019
$17.8M
cGMP Manufacture, Fill-Finish, Release, Analytical and Stability Testing and Stability Program of a Nanoparticle Based HIV Envelope Vaccine75N93022D00005 · NIAID · INTERNATIONAL AIDS VACCINE INITIATIVE · PI HASSELL, THOMAS · 2022 to 2025
$8.0M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00005 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WATSON, KAROL E · 2020 to 2025
$5.1M
NCATS NIH HHS UL1 TR000454NCATS NIH HHS UL1 TR002378NHLBI NIH HHS 75N92020D00005NIAID NIH HHS 75N93022D00005NIAID NIH HHS 75N93023D00005NIAID NIH HHS HHSN272201300006CNIAID NIH HHS N01 AI025456NIAID NIH HHS P30 AI050409NIAID NIH HHS U19 AI111211NIDA NIH HHS 75N95020D00005NIH HHS 272201300006CNIH HHS 75N93020D00005NIH HHS P51 OD011132ORFDO NIH HHS 75N99020D00005
6 · The paper itself

Abstract

Class II major histocompatibility complex peptide (MHC-IIp) multimers are precisely engineered reagents used to detect T cells specific for antigens from pathogens, tumors, and self-proteins. While the related Class I MHC/peptide (MHC-Ip) multimers are usually produced from subunits expressed in E. coli, most Class II MHC alleles cannot be produced in bacteria, and this has contributed to the perception that MHC-IIp reagents are harder to produce. Herein, we present a robust constitutive expression system for soluble biotinylated MHC-IIp proteins that uses stable lentiviral vector-transduced derivatives of HEK-293T cells. The expression design includes allele-specific peptide ligands tethered to the amino-terminus of the MHC-II β chain via a protease-cleavable linker. Following cleavage of the linker, HLA-DM is used to catalyze efficient peptide exchange, enabling high-throughput production of many distinct MHC-IIp complexes from a single production cell line. Peptide exchange is monitored using either of two label-free methods, native isoelectric focusing gel electrophoresis or matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry of eluted peptides. Together, these methods produce MHC-IIp complexes that are highly homogeneous and that form the basis for excellent MHC-IIp multimer reagents. © 2021 Wiley Periodicals LLC. Basic Protocol 1: Lentivirus production and expression line creation Support Protocol 1: Six-well assay for estimation of production cell line yield Support Protocol 2: Universal ELISA for quantifying proteins with fused leucine zippers and His-tags Basic Protocol 2: Cultures for production of Class II MHC proteins Basic Protocol 3: Purification of Class II MHC proteins by anti-leucine zipper affinity chromatography Alternate Protocol 1: IMAC purification of His-tagged Class II MHC Support Protocol 3: Protein concentration measurements and adjustments Support Protocol 4: Polishing purification by anion-exchange chromatography Support Protocol 5: Estimating biotinylation percentage by streptavidin precipitation Basic Protocol 4: Peptide exchange Basic Protocol 5: Analysis of peptide exchange by matrix-assisted laser desorption/ionization (MALDI) mass spectrometry Alternate Protocol 2: Native isoelectric focusing to validate MHC-II peptide loading Basic Protocol 6: Multimerization Basic Protocol 7: Staining cells with Class II MHC tetramers.

Indexed as

Escherichia coliHistocompatibility Antigens Class IIHEK293 CellsHumansIndicators and ReagentsStaining and LabelingHistocompatibility Antigens Class IIIndicators and Reagentsantigen-specific T cellsClass II MHC multimersClass II MHC tetramersflow cytometrylentiviral transductionprotein engineeringprotein expressionprotein purification

Identifiers

PMID33539685
PMCPMC7880703
OpenAlexW3128254355

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.